These inclusion criteria ensured the study population represented patients most likely to benefit from pharmacological weight management
As a glucagon-like peptide-1 receptor agonist (GLP-1 RA), semaglutide exerts its effects through various mechanisms within the body
[2] Common examples available in the UK include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro), which is a dual GLP-1 and GIP receptor agonist
However, as an observational target trial emulation, the study cannot establish causality, and residual or unmeasured confounding remains possible
People with significant weight to lose
GSSG is an important intermediate in the redox cycle of glutathione and is involved in various cellular processes